Listen to the article
Weight-Loss Drug Prescriptions Surge Unevenly Across U.S. as Prices Expected to Drop
With President Donald Trump securing agreements to lower prices on popular weight-loss medications, the already booming market for GLP-1 drugs like Ozempic and Mounjaro is poised for even greater expansion. A new analysis reveals striking regional disparities in how Americans are accessing these medications, with usage patterns closely mirroring the nation’s obesity epidemic.
According to insurance claims data compiled by Pennsylvania-based health analytics firm Purple Lab and published by GLP-1 Newsroom, prescription rates for these medications vary dramatically between states. The highest concentrations appear in the South, Midwest, and Appalachia—regions that traditionally struggle with higher rates of obesity and diabetes.
West Virginia leads the nation with 24% of its population receiving GLP-1 prescriptions, followed by Kentucky at 22%. Other states with notably high prescription rates include Louisiana and Oklahoma (both at 20%), Alabama and Mississippi (both at 19%), and North Dakota (18%). In total, 17 states reported that at least 15% of their populations had received these medications.
By contrast, coastal and Western states show significantly lower usage rates. Hawaii has the nation’s lowest prescription rate at just 5%, while other states with relatively low usage include Rhode Island (7.5%), Utah, Colorado, Arizona, Oregon, and Nevada (all 8%).
Experts note that the data, drawn from commercial and government insurance claims, likely understates actual usage since it excludes cash payments, telehealth prescriptions, compounded versions, and uninsured patients.
Dr. Brett Osborn, a Florida neurologist and longevity expert who prescribes GLP-1 medications to patients, suggests the regional disparities reflect different health challenges across the country.
“These agents are primarily prescribed for type 2 diabetes, but the tides are turning — and soon, in my humble opinion, they will be used more to treat obesity or categorically ‘overweight’ individuals, absent diabetes, although there is typically a high degree of crossover between the two conditions,” Osborn told Fox News Digital.
The prescription patterns closely align with obesity rates documented in the Trust for America’s Health’s State of Obesity report. Based on 2024 CDC data, this report identifies West Virginia as having the nation’s highest adult obesity rate (41.4%), followed by Mississippi (40.4%), Louisiana (39.2%), Alabama (38.7%), and Arkansas (38.4%).
Notably, nine of the ten states with the highest obesity rates also report that at least 15% of their populations have GLP-1 prescriptions. The report also revealed that for the first time in tracking history, no state had an adult obesity rate below 25%.
The medications, initially developed for diabetes management, have gained tremendous popularity for weight loss after studies showed their effectiveness. Their potential applications continue to expand, with researchers investigating their benefits for cardiovascular disease, addiction management, cognitive decline, and even as complementary treatments for cancer.
“Prescribing practices and indications are expanding rapidly, and therefore, we must be careful about our conclusions,” Osborn cautioned, while acknowledging that the medications are particularly valuable in states where obesity and diabetes have reached epidemic proportions.
Public health experts emphasize that medication alone cannot solve America’s obesity crisis. “Structural barriers to healthy eating and physical activity need continued policy attention and investment,” said Dr. J. Nadine Gracia, president and CEO of Trust for America’s Health. “It is vital that government and other sectors invest in – not cut – proven programs that support good nutrition and physical activity and ensure they reach all communities.”
As prices potentially decrease under the new agreements, access to these medications could widen further, potentially altering the landscape of obesity treatment nationwide. However, the regional disparities highlight broader public health challenges that may require more comprehensive solutions beyond pharmaceutical interventions.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
10 Comments
While the increased availability of weight-loss medications is a positive step, I wonder if over-reliance on these drugs could distract from the broader, systemic changes needed to promote healthier communities. A balanced approach is likely required.
That’s a fair point. Medications should be part of a holistic strategy that also focuses on education, community programs, and policy changes to address the root causes of obesity.
This data provides an interesting snapshot of the evolving landscape of weight-loss medication usage in the US. I look forward to seeing how these trends develop and what further insights emerge about the factors shaping regional differences.
This data highlights the need for a comprehensive, nationwide approach to addressing the obesity epidemic. Providing equal access to effective treatments and promoting preventative healthcare measures could help reduce these geographic inequalities.
Absolutely. Tackling the root causes of obesity, from nutrition to physical activity, will be crucial in developing sustainable solutions.
It’s encouraging to see the potential for increased access to weight-loss treatments, but the uneven distribution is concerning. Ensuring equitable access to these medications, as well as broader preventative measures, should be a priority.
Agreed. A holistic, nationwide approach is needed to address the complex challenge of obesity and promote better health outcomes for all Americans.
The regional disparities highlighted in this data are quite stark. I’m curious to learn more about the social, economic, and cultural factors that may be driving these differences in weight-loss medication usage across the country.
Interesting to see how weight-loss medications are impacting obesity rates across the US. Curious to learn more about the regional disparities and how access to these treatments varies by state.
Yes, it’s a complex issue with many factors at play. Access to affordable healthcare and education around healthy lifestyles likely play a big role in these regional differences.